Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...
Stocktwits on MSN
Amgen Stock Extends Rally After-Hours As CEO Hypes New Cholesterol Drug Data On Jim Cramer’s Show
CEO Bob Bradway told CNBC’s Jim Cramer that nearly all heart attacks stem from “modifiable” risks like high LDL, emphasizing the need for early cholesterol control. ・Late-stage trial data showed that ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Credit: Amgen. The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha (evolocumab) Pushtronix ® System (single-dose on-body infusor with prefilled ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware has ...
Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...
Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback